

Release No 155

19 April 2005

### **Head-to-head study of Cipralex® and citalopram**

In the peer-reviewed scientific journal *International Clinical Psychopharmacology*, a team of French scientists recently announced the results of a head-to-head study which confirm that Cipralex®/Lexapro® is significantly more effective than citalopram in the treatment of depression. No studies of this kind have previously been conducted with Cipralex®.

The study shows that Cipralex® is significantly more effective than citalopram in the treatment of depression and that both drugs are particularly well-tolerated. The study confirms the consistent findings of earlier scientific studies, which show that Cipralex® is superior to citalopram.

The double-blind randomised study enrolled 294 patients. The patients were treated either with 20mg Cipralex® or 40mg citalopram for eight weeks. The results at the completion of the study show that Cipralex® is significantly more effective in terms of the primary endpoint – improvement of disease symptoms ( $p<0.05$ ). The number of patients responding to the treatment was significantly higher in the group of patients treated with Cipralex® ( $p=0.009$ ), and the number of symptom-free patients at the end of the study was also significantly higher among the patients who had received Cipralex® ( $p<0.05$ ).

Both Cipralex® and citalopram were particularly well-tolerated in the study. However, a significantly higher number of patients treated with Cipralex® completed the study compared with patients treated with citalopram ( $p<0.05$ ).

The content of this release will have no influence on the Lundbeck Group's expectations for the financial result for 2005.

#### **Investor and Media contact**

- Steen Juul Jensen, Vice President, tel +45 36 43 30 06
- Jacob Tolstrup, Investor Relations Manager, tel +45 36 43 30 79
- Helle Hedegaard Juhl, Media Relations Officer, tel +45 36 43 41 68.

**H. Lundbeck A/S**

Ottiliavej 9  
DK-2500 Valby København

Tel +45 36 30 13 11  
Fax +45 36 43 82 62

E-mail [investor@lundbeck.com](mailto:investor@lundbeck.com)  
[www.lundbeck.com](http://www.lundbeck.com)



H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders. In 2004, the company's revenue was DKK 9.7 billion. The number of employees is approx. 5,000.